|
Market Closed -
Other stock markets
|
Pre-market 01:13:57 am | |||
| 76.67 EUR | +1.95% |
|
76.80 | +0.17% |
| May. 20 | European Equities Traded in US as ADRs Rise in Wednesday Trading | MT |
| May. 20 | When I buy a CAC 40 ETF, does my money actually go to French companies? |  |
Business description: Sanofi
- pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases;
- human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2025, the group had 37 production sites worldwide.
Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Number of employees: 74,846
Sales by Activity: Sanofi
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Biopharma | - | - | 41.21B | 43.95B | 46.23B |
Consumer Healthcare | 4.52B | 5.14B | 5.23B | - | - |
Pharmaceuticals Excl. Consumer Healthcare | 27.23B | 31.34B | - | - | - |
Vaccines | 7.42B | 8.9B | - | - | - |
Others | - | 7M | - | 339M | 487M |
Geographical breakdown of sales: Sanofi
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
United States | 14.38B | 18.28B | 18.51B | 19.99B | 22.18B |
Rest of The World | 7.85B | 8.39B | 13.46B | 12.07B | 9.66B |
Europe (Excluding France) | - | - | 8.01B | 7.21B | 7.46B |
China | 2.72B | 3.12B | - | - | 2.62B |
France | - | - | 2.38B | 1.81B | 1.71B |
Europe (Excl. Russia) | 9.76B | 10B | - | - | - |
Russia | 575M | 674M | - | - | - |
Brazil | 815M | 927M | - | - | - |
North America (Excluding United States) | - | - | 704M | - | - |
Japan | 1.66B | 1.61B | - | - | - |
Executive Committee: Sanofi
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
Madeleine Roach
COO | Chief Operating Officer | 42 | 2023-09-30 |
| Investor Relations Contact | 52 | 2024-03-14 |
Composition of the Board of Directors: Sanofi
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
Barbara Lavernos
BRD | Director/Board Member | 58 | 2021-04-29 |
Wolfgang Laux
BRD | Director/Board Member | 58 | 2021-03-31 |
Carole Ferrand
BRD | Director/Board Member | 55 | 2022-05-02 |
Emile Voest
BRD | Director/Board Member | 66 | 2022-05-02 |
Antoine Yver
BRD | Director/Board Member | 68 | 2022-05-02 |
Frédéric Oudéa
CHM | Chairman | 62 | 2023-05-24 |
| Director/Board Member | 55 | 2024-04-29 |
Holdings: Sanofi
| Name | Equities | % | Valuation |
|---|---|---|---|
SANOFI 0.99% | 11,962,777 | 0.99% | 1 120 M $ |
SANOFI 60.4% | 13,909,587 | 60.4% | 698 M $ |
SANOFI INDIA LIMITED 60.4% | 13,909,587 | 60.4% | 499 M $ |
SANOFI INDIA LIMITED 7.93% | 1,157,926 | 7.93% | 150 M $ |
MEIRAGTX HOLDINGS PLC 13.18% | 12,197,737 | 13.18% | 112 M $ |
NOVAVAX, INC. 4.22% | 6,880,481 | 4.22% | 55 M $ |
ANAPTYSBIO, INC. 2.86% | 821,917 | 2.86% | 54 M $ |
EUROAPI 29.6% | 28,298,074 | 29.6% | 45 M $ |
SENSORION 13.87% | 71,428,571 | 13.87% | 34 M $ |
AGOMAB THERAPEUTICS NV 5.71% | 2,783,096 | 5.71% | 30 M $ |
Company details: Sanofi
Group companies: Sanofi
| Name | Category and Sector |
|---|---|
Pharmaceuticals: Major
| |
Pharmaceuticals: Major
| |
Sanofi Healthcare India Pvt Ltd.
 Sanofi Healthcare India Pvt Ltd. BiotechnologyHealth Technology Develops and manufactures vaccines |
Biotechnology
|
Sanofi Aventis Paraguay SA | |
Sanofi Manufacturing Pte Ltd. |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.95% | +5.43% | -18.02% | -24.55% | 107B | |
| -0.25% | +0.31% | +36.39% | +130.32% | 909B | |
| -0.30% | -0.48% | +49.24% | +44.31% | 552B | |
| -0.68% | +1.82% | +14.85% | +46.30% | 375B | |
| -0.42% | +2.53% | +24.56% | +13.82% | 332B | |
| +0.50% | +1.34% | +33.90% | +16.15% | 291B | |
| -0.42% | +1.49% | +27.07% | +30.97% | 287B | |
| -1.09% | -0.40% | +44.93% | -2.16% | 279B | |
| +0.31% | -3.61% | -36.78% | -49.84% | 199B | |
| +0.25% | -1.45% | +20.57% | +48.41% | 179B | |
| Average | -0.06% | +1.21% | +19.67% | +25.37% | 351.01B | |
| Weighted average by Cap. | -0.32% | +1.17% | +28.09% | +49.55% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SAN Stock
- Company Sanofi
Select your edition
All financial news and data tailored to specific country editions
